
Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma
June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho
Updated on: October 15,2023
258

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma
June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho
Updated on:October 15,2023
258
